Pantethine Improves Psoriasis Scores in 24-Patient Trial Over 12 Weeks
Updated
Updated · LabRoots · Nov 8
Pantethine Improves Psoriasis Scores in 24-Patient Trial Over 12 Weeks
3 articles · Updated · LabRoots · Nov 8
Summary
A 24-person randomized trial found oral pantethine plus standard topical therapy improved plaque psoriasis severity more than topical treatment alone after 12 weeks.
Researchers linked the benefit to the Vanin-pantethine pathway: higher Vanin activity depleted pantethine in dendritic cells, increased cholesterol buildup and immune activation, and appeared to drive inflammation.
Mouse and cell experiments supported that mechanism, with pantethine treatment, Vanin blockade, or Vnn3 deletion reducing skin thickening and inflammatory immune-cell infiltration.
No treatment-related adverse effects were reported, and gains were especially notable in participants with high blood lipid levels.
The study called the result proof of concept rather than confirmation, with larger multi-center trials still needed to test durability, safety, and possible use in other autoimmune diseases.